Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

Similar articles for PubMed (Select 23092510)

1.

Retraction: Structure based sequence analysis & epitope prediction of gp41 HIV1 envelope glycoprotein isolated in Pakistan.

Jafri SS, Kiran S, Jamal SB, Shah M.

Genet Vaccines Ther. 2012 Oct 23;10(1):10. doi: 10.1186/1479-0556-10-10. No abstract available.

2.

Structure based sequence analysis & epitope prediction of gp41 HIV1 envelope glycoprotein isolated in Pakistan.

Jafri SS, Kiran S, Jamal SB, Shah M.

Genet Vaccines Ther. 2012 Jun 20;10(1):4. doi: 10.1186/1479-0556-10-4.

3.

Characterization of HIV1-PAR, a macrophage-tropic strain: cell tropism, virus/cell entry and nucleotide sequence of the envelope glycoprotein.

Schmidtmayerova H, Gayet O, Guettari N, Bolmont C, Hirsch I, Chermann JC.

Res Virol. 1993 Jan-Feb;144(1):21-6.

PMID:
8446773
4.

Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding.

Binley JM, Ditzel HJ, Barbas CF 3rd, Sullivan N, Sodroski J, Parren PW, Burton DR.

AIDS Res Hum Retroviruses. 1996 Jul 1;12(10):911-24.

PMID:
8798976
5.
6.

Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints.

Tian Y, Ramesh CV, Ma X, Naqvi S, Patel T, Cenizal T, Tiscione M, Diaz K, Crea T, Arnold E, Arnold GF, Taylor JW.

J Pept Res. 2002 Jun;59(6):264-76.

PMID:
12010517
7.

Structural variability of env and gag gene products from a highly cytopathic strain of HIV-1.

Yahi N, Fantini J, Hirsch I, Chermann JC.

Arch Virol. 1992;125(1-4):287-98.

PMID:
1642554
8.

Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure.

Poumbourios P, el Ahmar W, McPhee DA, Kemp BE.

J Virol. 1995 Feb;69(2):1209-18.

11.

Progress towards the development of a HIV-1 gp41-directed vaccine.

McGaughey GB, Barbato G, Bianchi E, Freidinger RM, Garsky VM, Hurni WM, Joyce JG, Liang X, Miller MD, Pessi A, Shiver JW, Bogusky MJ.

Curr HIV Res. 2004 Apr;2(2):193-204. Review.

PMID:
15078183
12.
15.

Functional evolution of the HIV-1 envelope glycoprotein 120 association site of glycoprotein 41.

Poumbourios P, Maerz AL, Drummer HE.

J Biol Chem. 2003 Oct 24;278(43):42149-60. Epub 2003 Aug 15.

17.

Definition of an immunodominant T cell epitope contained in the envelope gp41 sequence of HIV-1.

Bell SJ, Cooper DA, Kemp BE, Doherty RR, Penny R.

Clin Exp Immunol. 1992 Jan;87(1):37-45.

18.

HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41.

Rey-Cuillé MA, Svab J, Benferhat R, Krust B, Briand JP, Muller S, Hovanessian AG.

J Pharm Pharmacol. 2006 Jun;58(6):759-67.

PMID:
16734977
19.
20.

Recombinant multi-epitope vaccine induce predefined epitope-specific antibodies against HIV-1.

Li H, Liu ZQ, Ding J, Chen YH.

Immunol Lett. 2002 Nov 1;84(2):153-7.

PMID:
12270553
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk